Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Interest & Investment Income: 2016-2024

Historic Interest & Investment Income for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $14.0 million.

  • Collegium Pharmaceutical's Interest & Investment Income fell 5.00% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year decrease of 42.09%. This contributed to the annual value of $14.0 million for FY2024, which is 10.50% down from last year.
  • According to the latest figures from FY2024, Collegium Pharmaceutical's Interest & Investment Income is $14.0 million, which was down 10.50% from $15.6 million recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's Interest & Investment Income ranged from a high of $15.6 million in FY2023 and a low of $12,000 during FY2021.
  • For the 3-year period, Collegium Pharmaceutical's Interest & Investment Income averaged around $10.2 million, with its median value being $14.0 million (2024).
  • As far as peak fluctuations go, Collegium Pharmaceutical's Interest & Investment Income plummeted by 94.83% in 2021, and later skyrocketed by 8,625.00% in 2022.
  • Over the past 5 years, Collegium Pharmaceutical's Interest & Investment Income (Yearly) stood at $232,000 in 2020, then plummeted by 94.83% to $12,000 in 2021, then soared by 8,625.00% to $1.0 million in 2022, then soared by 1,391.40% to $15.6 million in 2023, then declined by 10.50% to $14.0 million in 2024.